Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.

Our results demonstrate that a delayed increase in CSF protein concentration is expected during nusinersen treatment for SMA types 2 and 3. This might reflect the medication's effect and a possible therapeutic biochemical marker.